HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wu, K. H. Articles by Han, Z. C. Search for Related Content PubMed PubMed Citation Articles by Wu, K. H. Articles by Han, Z. C. Related Collections Transplantation - heart

Eur J Cardiothorac Surg 2006;30:770-781
© 2006 Elsevier Science NL

Reviews

Cellular therapy and myocardial tissue engineering: the role of adult stem and progenitor cells

^a Pediatric Cardiac Center, Department of Surgery, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Beijing 100037, China
^b State Key Laboratory of Experimental Hematology, National Research Center for Stem Cell Engineering and Technology, Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

Received 11 February 2006; received in revised form 2 August 2006; accepted 7 August 2006.

^_* Corresponding author. Tel.: +86 10 88398188; fax: +86 10 68332747. (Email: pumcwu{at}yahoo.com.cn).

Acquired cardiovascular diseases and complex congenital heart diseases are leading causes of morbidity and mortality. Cellular therapy and tissue engineering are emerging as promising alternative approaches to treat cardiovascular diseases. Cellular therapy involves isolating cells and delivering the cells to the site of cardiac injury to restore blood flow and contractility to previously infarcted, scarred or dysfunctional heart. Myocardial tissue engineering, engineered heart tissue by seeding cells in three-dimensional matrices of biodegradable polymers or cell sheet engineering without artificial scaffolds to form new myocardial constructs. Questions are common to both these approaches, such as the best cell source and optimal conditions for therapeutic application. The capabilities of stem cells for pluripotency and long-term self-renewal make it an ideal source for myocardial tissue engineering and cell therapy. We review the current understanding of postnatal adult stem and progenitor cells in cellular therapy and myocardial tissue engineering from a surgical view point, and highlight the latest advances in these exciting fields.

Key Words: Tissue engineering • Stem cells • Cell therapy • Myocardial infarction • Congenital heart defects

This article has been cited by other articles:

				K. H. Wu, B. Zhou, C. T. Yu, B. Cui, S. H. Lu, Z. C. Han, and Y. L. Liu Therapeutic Potential of Human Umbilical Cord Derived Stem Cells in a Rat Myocardial Infarction Model Ann. Thorac. Surg., April 1, 2007; 83(4): 1491 - 1498. [Abstract] [Full Text] [PDF]